UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 10 von 56
Datensatz exportieren als...
BibTeX
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1702-1712
Prekovic, Stefan
van Royen, Martin E
Voet, Arnout R D
Geverts, Bart
Houtman, Rene
Melchers, Diana
Zhang, Kam Y J
Van den Broeck, Thomas
Smeets, Elien
Spans, Lien
Houtsmuller, Adriaan B
Joniau, Steven
Claessens, Frank
Helsen, Christine
2016
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Prekovic, Stefan
van Royen, Martin E
Voet, Arnout R D
Geverts, Bart
Houtman, Rene
Melchers, Diana
Zhang, Kam Y J
Van den Broeck, Thomas
Smeets, Elien
Spans, Lien
Houtsmuller, Adriaan B
Joniau, Steven
Claessens, Frank
Helsen, Christine
Titel
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Ist Teil von
Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1702-1712
Ort / Verlag
United States
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702-12. ©2016 AACR.
Sprache
Englisch
Identifikatoren
ISSN: 1535-7163
eISSN: 1538-8514
DOI: 10.1158/1535-7163.mct-15-0892
Titel-ID: cdi_proquest_miscellaneous_1811894811
Format
–
Schlagworte
Amino Acid Substitution
,
Androgen Antagonists - pharmacology
,
Antineoplastic Agents - chemistry
,
Antineoplastic Agents - pharmacology
,
Cell Line, Tumor
,
Cluster Analysis
,
Codon
,
Drug Resistance, Neoplasm - genetics
,
Gene Expression Profiling
,
Gene Expression Regulation, Neoplastic
,
Humans
,
Ligands
,
Models, Molecular
,
Molecular Conformation
,
Mutation
,
Phenylthiohydantoin - analogs & derivatives
,
Phenylthiohydantoin - chemistry
,
Phenylthiohydantoin - pharmacology
,
Protein Binding
,
Receptors, Androgen - chemistry
,
Receptors, Androgen - genetics
,
Receptors, Androgen - metabolism
,
Structure-Activity Relationship
,
Transcriptional Activation
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX